Moxetumomab Pasudotox-tdfk

Phase 1Small molecule

Moxetumomab Pasudotox-tdfk is one of 22 small molecule programs targeting Hairy Cell Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hairy Cell LeukemiaActive, not recruiting

Hairy Cell LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Hairy Cell Leukemia

#DrugCompanyPhaseTrials

Braftovi

Rituxan

7 3

Gazyva

Roche

Phase 2

2 4

Nipent

Pfizer

Phase 2

1 5

Mektovi

Pfizer

Phase 2

1 6

Leustatin

EMD Serono

Phase 2

4 7

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

3 8

Tylenol

KKenvue Brands

Phase 2

2 9

Benadryl

PParkedale

Phase 2

2 10

Treanda

AAzurity Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Active, not recruiting

Hairy Cell Leukemia

NCT03805932

Clinical

Trials by Indication[1]

Hairy Cell Leukemia1 trial

A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03805932·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Moxetumomab Pasudotox-tdfk. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Moxetumomab Pasudotox-tdfk compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Moxetumomab Pasudotox-tdfk. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Moxetumomab Pasudotox-tdfk

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Hairy Cell Leukemia1 trial

References

Drug Info

Quick Facts

Related News